MCID: MCN001
MIFTS: 54

Mucinous Adenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Mucinous Adenocarcinoma

MalaCards integrated aliases for Mucinous Adenocarcinoma:

Name: Mucinous Adenocarcinoma 12 14 69
Mucin-Producing Adenocarcinoma 12 69
Pseudomyxoma Peritonei with Unknown Primary Site 12
Mucin-Secreting Adenocarcinoma 12
Mucin-Secreting Carcinoma 12
Adenocarcinoma, Mucinous 41
Mucous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3030
MeSH 41 D002288
SNOMED-CT 64 72495009 900006

Summaries for Mucinous Adenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells originating in glandular tissue, which produce mucin.

MalaCards based summary : Mucinous Adenocarcinoma, also known as mucin-producing adenocarcinoma, is related to endometrial mucinous adenocarcinoma and ovarian mucinous adenocarcinoma. An important gene associated with Mucinous Adenocarcinoma is KRT7 (Keratin 7), and among its related pathways/superpathways are Endometrial cancer and Relaxin signaling pathway. The drugs Bevacizumab and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include colon, prostate and appendix, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Mucinous Adenocarcinoma

Diseases related to Mucinous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 384)
# Related Disease Score Top Affiliating Genes
1 endometrial mucinous adenocarcinoma 33.7 CDKN2A MUC1
2 ovarian mucinous adenocarcinoma 33.3 CDX2 KRT20 KRT7 MUC2
3 appendix adenocarcinoma 32.8 CDX2 KRT20 KRT7 MUC2
4 pseudomyxoma peritonei 31.0 CDX2 KRAS KRT20 KRT7 MUC1 MUC2
5 ovarian germ cell teratoma 30.4 KRT7 NKX2-1
6 thymus adenocarcinoma 30.3 CDX2 KRT20 KRT7
7 transverse colon cancer 30.2 KRT20 KRT7
8 ovarian large-cell neuroendocrine carcinoma 30.2 KRT20 KRT7
9 nephrogenic adenoma 30.2 KRT7 MUC1
10 sertoli-leydig cell tumor 30.0 KRT7 MUC1
11 villous adenoma 30.0 CDX2 KRAS KRT20 MUC1
12 dermoid cyst 29.9 KRT20 KRT7 MUC1
13 clear cell adenocarcinoma 29.9 KRT20 KRT7 TP53
14 mature teratoma 29.8 KRAS TP53
15 adenocarcinoma 29.8 CDKN2A EGFR KRAS MLH1 MUC1 TP53
16 vulva adenocarcinoma 29.8 CDKN2A CDX2 KRT20 KRT7
17 cystadenocarcinoma 29.8 KRT7 MUC1 MUC2 TP53
18 teratoma 29.7 CDX2 KRT20 KRT7 NKX2-1 TP53
19 microinvasive gastric cancer 29.7 CDX2 MLH1 MUC2
20 colon adenocarcinoma 29.7 KRAS KRT20 MLH1
21 adenoma 29.7 KRAS KRT7 MLH1 MUC2 TP53
22 cystadenoma 29.6 KRT20 KRT7 MUC1 MUC2
23 adenocarcinoma in situ 29.4 CDKN2A CDX2 KRAS KRT20 KRT7
24 large cell neuroendocrine carcinoma 29.3 EGFR KRT20 KRT7 NKX2-1
25 cystic teratoma 29.2 CDX2 KRT20 KRT7 MUC2 NKX2-1 TP53
26 peritoneal mesothelioma 29.1 CDKN2A EGFR MUC1
27 mucoepidermoid carcinoma 29.1 EGFR KRT7 MUC1 MUC2
28 appendix cancer 28.9 CDX2 KRAS KRT20 KRT7 MUC1 MUC2
29 in situ carcinoma 28.9 CDKN2A EGFR TP53
30 transitional cell carcinoma 28.8 EGFR KRT20 KRT7 TP53
31 endocervical adenocarcinoma 28.7 CDKN2A CDX2 KRT20 KRT7 TP53
32 horseshoe kidney 28.5 CDX2 EGFR KRT20 KRT7 NKX2-1
33 renal cell carcinoma, nonpapillary 28.5 EGFR KRT20 KRT7 MUC1 NKX2-1
34 pancreas adenocarcinoma 27.9 CDKN2A EGFR KRAS MUC1 MUC2 TP53
35 ovarian cancer 27.9 EGFR KRAS KRT7 MLH1 MUC1 MUC2
36 endometrial cancer 27.6 CDKN2A EGFR KRAS KRT20 KRT7 MLH1
37 gallbladder cancer 27.4 CDKN2A EGFR KRAS MLH1 MUC1 MUC2
38 colorectal adenocarcinoma 27.2 CDX2 EGFR KRAS KRT20 KRT7 MLH1
39 lung cancer susceptibility 3 26.7 CDKN2A CDX2 EGFR KRAS KRT20 KRT7
40 gastric cancer 26.6 CDKN2A CDX2 EGFR KRAS KRT20 MLH1
41 colorectal cancer 25.6 ALK CDKN2A CDX2 EGFR KRAS KRT20
42 colon mucinous adenocarcinoma 12.2
43 mucinous adenocarcinoma of ovary 12.1
44 mucinous adenocarcinoma of the appendix 12.1
45 cervical mucinous adenocarcinoma 12.0
46 ampulla of vater mucinous adenocarcinoma 12.0
47 bile duct mucinous adenocarcinoma 12.0
48 uterine ligament mucinous adenocarcinoma 12.0
49 fallopian tube mucinous adenocarcinoma 12.0
50 signet ring cell variant cervical mucinous adenocarcinoma 12.0

Graphical network of the top 20 diseases related to Mucinous Adenocarcinoma:



Diseases related to Mucinous Adenocarcinoma

Symptoms & Phenotypes for Mucinous Adenocarcinoma

GenomeRNAi Phenotypes related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.32 EGFR KRAS MUC1
2 Decreased viability GR00106-A-0 9.32 KRAS
3 Decreased viability GR00221-A-1 9.32 EGFR KRAS
4 Decreased viability GR00221-A-2 9.32 KRAS
5 Decreased viability GR00221-A-4 9.32 EGFR
6 Decreased viability GR00301-A 9.32 KRAS
7 Decreased viability GR00381-A-1 9.32 KRAS
8 Decreased cell migration GR00055-A-1 9.26 ALK EGFR KRAS MUC1

MGI Mouse Phenotypes related to Mucinous Adenocarcinoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.11 KRT7 CDKN2A MLH1 CDX2 MUC2 EGFR
2 homeostasis/metabolism MP:0005376 10.07 MLH1 CDX2 MUC2 EGFR ALK KRAS
3 endocrine/exocrine gland MP:0005379 10.06 MLH1 CDX2 MUC2 EGFR ALK KRAS
4 digestive/alimentary MP:0005381 10.03 MLH1 CDX2 MUC2 EGFR KRAS CDKN2A
5 neoplasm MP:0002006 9.97 MLH1 CDX2 MUC2 EGFR NKX2-1 ALK
6 reproductive system MP:0005389 9.76 MLH1 CDX2 EGFR ALK KRAS CDKN2A
7 pigmentation MP:0001186 9.65 EGFR ALK KRAS CDKN2A TP53
8 respiratory system MP:0005388 9.5 MLH1 EGFR ALK KRAS CDKN2A NKX2-1
9 skeleton MP:0005390 9.17 CDKN2A CDX2 EGFR ALK KRAS NKX2-1

Drugs & Therapeutics for Mucinous Adenocarcinoma

Drugs for Mucinous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 209)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
2
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
3
Cetuximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 205923-56-4 56842117 2333
4
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
5
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
6
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
7
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
8
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
9
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
10
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
11
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
12
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
13
Topotecan Approved, Investigational Phase 2, Phase 3, Phase 1 119413-54-6, 123948-87-8 60700
14
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 6442177
15
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
16
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 46835353 6436030 5284616
17
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
18
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
19
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
20
Trametinib Approved Phase 2, Phase 3,Phase 1 871700-17-3 11707110
21
Metformin Approved Phase 2, Phase 3,Phase 1 657-24-9 4091 14219
22
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
23
Olaparib Approved Phase 2, Phase 3,Phase 1 763113-22-0 23725625
24
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
25
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
26
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
27
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1 56-86-0 33032
28
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
29
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
30
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
31
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
32
Cediranib Investigational Phase 2, Phase 3,Phase 1 288383-20-0 9933475
33
Maleic acid Experimental Phase 2, Phase 3,Phase 1 110-16-7 444266
34 Alkylating Agents Phase 3,Phase 2,Phase 1
35 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
36 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
37 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
38 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
39 Antidotes Phase 3,Phase 2,Phase 1
40 Antimetabolites Phase 3,Phase 2,Phase 1
41 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
42 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
43 Calcium, Dietary Phase 3,Phase 2,Phase 1
44 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
45 Micronutrients Phase 3,Phase 2,Phase 1,Early Phase 1
46 Mitomycins Phase 3
47 Nucleic Acid Synthesis Inhibitors Phase 3
48 Protective Agents Phase 3,Phase 2,Phase 1
49 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
50 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 177)

# Name Status NCT ID Phase Drugs
1 Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer Unknown status NCT01167725 Phase 3 FOLFIRI regimen;FOLFOX regimen;capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C;oxaliplatin
2 Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer Unknown status NCT00002896 Phase 3 chemotherapy;fluorouracil;leucovorin calcium
3 High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer Completed NCT00004150 Phase 3 fluorouracil;leucovorin calcium
4 Edrecolomab in Treating Patients With Stage II Colon Cancer Completed NCT00002968 Phase 3
5 Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Completed NCT00005036 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
6 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
7 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
8 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
9 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
10 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
11 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
12 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
13 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
14 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
15 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan Hydrochloride;Trametinib
16 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
17 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
18 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
19 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
20 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
21 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
22 Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Active, not recruiting NCT00217737 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin
23 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
24 Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Active, not recruiting NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
25 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Active, not recruiting NCT01081262 Phase 3 Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
26 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
27 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
28 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
29 Comparison of Adjuvant Chemotherapy Regimens in Treating Patients With Stage II or Stage III Rectal Cancer Who Are Receiving Radiation Therapy and Fluorouracil Before or After Surgery Terminated NCT00068692 Phase 3 capecitabine;fluorouracil;leucovorin calcium;irinotecan hydrochloride;oxaliplatin
30 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
31 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
32 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
33 Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer Unknown status NCT02112552 Phase 2 Paclitaxel;Carboplatin
34 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
35 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
36 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy Completed NCT00004547 Phase 2 Postoperative dwell with paclitaxel and 5-FU
37 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
38 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
39 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
40 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
41 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2 Nintedanib
42 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
43 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00888173 Phase 2 Brivanib Alaninate
44 Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer Completed NCT00100841 Phase 2 oxaliplatin;leucovorin calcium;fluorouracil
45 Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2 Paclitaxel;Dexamethasone;Cimetidine;Diphenhydramine
46 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel
47 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
48 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer Completed NCT00008138 Phase 2 carboplatin;paclitaxel
49 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride
50 Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2 carboplatin;docetaxel;erlotinib hydrochloride

Search NIH Clinical Center for Mucinous Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma, mucinous

Genetic Tests for Mucinous Adenocarcinoma

Anatomical Context for Mucinous Adenocarcinoma

MalaCards organs/tissues related to Mucinous Adenocarcinoma:

38
Colon, Prostate, Appendix, Ovary, Lung, Liver, Pancreas

Publications for Mucinous Adenocarcinoma

Articles related to Mucinous Adenocarcinoma:

(show top 50) (show all 579)
# Title Authors Year
1
Hemorrhagic Brain Metastases in a Patient with Anaplastic Lymphoma Kinase (ALK)-Rearranged Invasive Mucinous Adenocarcinoma of the Lung. ( 29371584 )
2018
2
Diagnosis, clinicopathological characteristics and prognosis of pulmonary mucinous adenocarcinoma. ( 29375717 )
2018
3
Pseudomyxoma Peritonei Arising From Urachal Mucinous Adenocarcinoma. ( 29024737 )
2018
4
Case of mucinous adenocarcinoma of the lung associated with congenital pulmonary airway malformation in a neonate. ( 29441110 )
2018
5
Perianal Paget disease secondary to pagetoid spread of mucinous adenocarcinoma of the anal canal. ( 29400297 )
2018
6
Right-colon mucinous adenocarcinoma mimicking a hydatid cyst. ( 29313694 )
2018
7
Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases. ( 28590015 )
2017
8
Sertoli-Leydig cell tumor of the ovary masquerading as a mucinous adenocarcinoma: a frozen section pitfall. ( 29081925 )
2017
9
Mucinous adenocarcinoma on perianal fistula. A rising entity? ( 28929316 )
2017
10
Mucinous adenocarcinoma of unknown primary presenting with dysphagia. ( 29223385 )
2017
11
Pulmonary Invasive Mucinous Adenocarcinoma and Mixed Invasive Mucinous/Non-Mucinous Adenocarcinoma- A Clinicopathological and Molecular Genetic Study with Survival Analysis. ( 28823574 )
2017
12
Mucinous adenocarcinoma arising in an end ileostomy - a video vignette. ( 28677338 )
2017
13
Cystic metastasis from a mucinous adenocarcinoma of duodenum mimicking type II choledochal cyst: A case report. ( 29290919 )
2017
14
Mucinous adenocarcinoma with lepidic pattern and with K-RAS mutation in a newborn with antenatal diagnosis of congenital pulmonary airway malformation. ( 28889407 )
2017
15
Comment on: External Validation of the Simplified Preoperative Assessment for Low-Grade Mucinous Adenocarcinoma of the Appendix. ( 29124485 )
2017
16
The Importance of Appendectomy in Surgery for Mucinous Adenocarcinoma of the Ovary. ( 28060142 )
2017
17
Biology of invasive mucinous adenocarcinoma of the lung. ( 29114467 )
2017
18
Fluorodeoxyglucose-avid pulmonary mucinous adenocarcinoma presenting with nonfluorodeoxyglucose-avid cystic brain lesions of unknown etiopathology: Brain magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography-computed tomography imaging features and additional value of whole-body positron emission tomography acquisition. ( 29199669 )
2017
19
Agenesis of the dorsal pancreas associated with mucinous adenocarcinoma and cystic teratoma: a case report and literature review. ( 28174646 )
2017
20
Primary mucinous adenocarcinoma of the vulva, intestinal type. ( 28791269 )
2017
21
Mucinous adenocarcinoma in association with hidradenitis suppurativa. ( 28597923 )
2017
22
Sonographic image of cervix epithelioid trophoblastic tumor coexisting with mucinous adenocarcinoma in a postmenopausal woman: A case report. ( 28930821 )
2017
23
Primary Mucinous Adenocarcinoma of the Thymus: A Case Report and Literature Review. ( 28956749 )
2017
24
Invasive mucinous adenocarcinoma with lepidic-predominant pattern coexisted with tuberculosis: a case report. ( 28687977 )
2017
25
KRAS mutation-positive mucinous adenocarcinoma originating in the thymus. ( 28932588 )
2017
26
Synchronous mucinous adenocarcinoma of the recto sigmoid revealed by and seeding an anal fistula. (A case report and review of the literature). ( 28641190 )
2017
27
Prognosis of Signet Ring Cell Carcinoma of the Colon and Rectum and their Distinction of Mucinous Adenocarcinoma with Signet Ring Cells. A Comparative Study. ( 28785968 )
2017
28
Metastatic Mucinous Adenocarcinoma and Carcinoid Tumor Arising From a Mature Cystic Teratoma of a Horseshoe Kidney. ( 28083486 )
2017
29
Urachal mucinous adenocarcinoma with pseudomyxoma peritonei: A case report. ( 28858081 )
2017
30
Endocrine Mucin-Producing Sweat Gland Carcinoma of the Eyelid Associated With Mucinous Adenocarcinoma. ( 28902090 )
2017
31
Giant mucinous adenocarcinoma of the appendix: a case report. ( 28756772 )
2017
32
Characteristics and prognostic factors of colorectal mucinous adenocarcinoma with signet ring cells. ( 29138597 )
2017
33
Mucinous adenocarcinoma in association with hidradenitis suppurativa: a new example of isoscartopic response. ( 29271499 )
2017
34
Primary mucinous adenocarcinoma of the lung: A case report and review of the literature. ( 28927134 )
2017
35
Vulvar Carcinosarcoma Composed of Intestinal-type Mucinous Adenocarcinoma Associated With Anaplastic Pleomorphic and Spindle Cell Carcinoma and Heterologous Chondrosarcomatous and Osteosarcomatous Elements: A Case Report and Review of the Literature. ( 28319579 )
2017
36
Molecular characteristics of multifocal invasive mucinous adenocarcinoma of the lung: Report of a rare case. ( 28851076 )
2017
37
Presentation of mucinous adenocarcinoma of renal pelvis masquerading as gross hydronephrosis: A histopathological surprise. ( 28702413 )
2017
38
Size of Non-lepidic Invasive Pattern Predicts Recurrence in Pulmonary Mucinous Adenocarcinoma: Morphologic Analysis of 188 Resected Cases with Reappraisal of Invasion Criteria. ( 27744658 )
2017
39
Mucinous Adenocarcinoma of the Suprapubic Cystostomy Tract without Bladder Involvement. ( 28670674 )
2017
40
Mixed mucinous adenocarcinoma and somatostatinoma of the ampulla of Vater associated with neurofibromatosis type 1. ( 28693748 )
2017
41
Pseudomyxoma peritonei with intrathoracic extension: a rare disease with rarer presentation from low-grade mucinous adenocarcinoma of the appendix. ( 26729823 )
2016
42
Advanced Mucinous Adenocarcinoma Arising from a Mature Cystic Teratoma: A Case Report and Literature Review. ( 27462234 )
2016
43
Appendicular mucinous adenocarcinoma associated with pseudomyxoma peritonei, a rare and difficult imaging diagnosis. ( 27239665 )
2016
44
Mucinous adenocarcinoma of the bladder: A case report and review of the literature. ( 27703678 )
2016
45
Regulation of multidrug resistance 1 expression by CDX2 in ovarian mucinous adenocarcinoma. ( 27060927 )
2016
46
mFOLFOX6 Chemotherapy after Resection of Anal Canal Mucinous Adenocarcinoma. ( 27239184 )
2016
47
Primary mucinous adenocarcinoma of the vulva: A case report and review of the literature. ( 27073659 )
2016
48
Acute Presentation of a Mucinous Adenocarcinoma of the Appendix. ( 27356817 )
2016
49
Squamous esophageal carcinoma and mucinous adenocarcinoma of the colon - an unusual association. ( 27151719 )
2016
50
Salivary mucinous adenocarcinoma of the mandible. ( 27167387 )
2016

Variations for Mucinous Adenocarcinoma

Expression for Mucinous Adenocarcinoma

Search GEO for disease gene expression data for Mucinous Adenocarcinoma.

Pathways for Mucinous Adenocarcinoma

Pathways related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.76 ALK CDKN2A EGFR KRAS MLH1 TP53
2
Show member pathways
12.36 CDKN2A EGFR KRAS TP53
3 12.36 ALK CDKN2A EGFR KRAS MLH1 TP53
4 12.3 CDKN2A EGFR KRAS TP53
5
Show member pathways
12.28 EGFR KRAS MUC1 TP53
6 11.99 CDKN2A KRAS TP53
7 11.96 EGFR KRAS TP53
8 11.95 EGFR KRAS MLH1 TP53
9 11.86 EGFR MLH1 TP53
10
Show member pathways
11.85 EGFR KRAS TP53
11 11.85 EGFR KRAS TP53
12
Show member pathways
11.85 CDKN2A EGFR KRAS TP53
13
Show member pathways
11.83 CDKN2A CDX2 EGFR KRAS MLH1 MUC2
14 11.78 CDKN2A KRAS TP53
15 11.74 CDKN2A KRAS MLH1 TP53
16 11.6 CDKN2A EGFR KRAS TP53
17 11.55 CDKN2A MLH1 TP53
18 11.47 EGFR KRAS TP53
19 11.34 CDKN2A EGFR TP53
20 11.12 CDKN2A EGFR KRAS TP53
21 10.93 CDKN2A TP53
22
Show member pathways
10.93 CDKN2A TP53

GO Terms for Mucinous Adenocarcinoma

Biological processes related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.76 CDKN2A KRAS NKX2-1 TP53
2 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.61 KRAS MUC1 MUC2
3 epithelial tube branching involved in lung morphogenesis GO:0060441 9.4 KRAS NKX2-1
4 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.37 MUC1 TP53
5 positive regulation of transcription, DNA-templated GO:0045893 9.35 CDKN2A CDX2 EGFR NKX2-1 TP53
6 positive regulation of cellular senescence GO:2000774 9.32 CDKN2A KRAS
7 replicative senescence GO:0090399 9.26 CDKN2A TP53
8 cerebral cortex cell migration GO:0021795 9.16 EGFR NKX2-1
9 Ras protein signal transduction GO:0007265 8.8 CDKN2A KRAS TP53

Sources for Mucinous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....